FDA Review Finds No Increased Risk of Prostate Cancer With Parkinson's Disease Treatments Containing Entacapone


A U.S. Food and Drug Administration (FDA) review of additional data found no increased risk of prostate cancer with the use of entacapone to treat Parkinson’s disease. The FDA conducted this review after an earlier trial—the Stalevo Reduction in Dyskinesia Evaluation–Parkinson's Disease (STRIDE-PD) trial—suggested this possible risk. As a result, the FDA’s recommendations for using entacapone (Comtan) and the combination of entacapone, carbidopa, and levodopa (Stalevo) will remain the same in the prescribing information.

The FDA alerted the public in March 2010 that it was aware of a clinical trial suggesting a possible increased risk of prostate cancer with the entacapone component of Stalevo. The FDA subsequently required the Stalevo manufacturer, Novartis, to conduct a study to further evaluate this potential risk, and the FDA also studied this issue independently using data from the Department of Veterans Affairs health-care system. Based on these additional studies, the FDA concluded that entacapone use is not associated with an increased risk of prostate cancer.

Medicines that contain entacapone with carbidopa and levodopa have been shown to effectively treat symptoms of Parkinson’s disease such as muscle stiffness, tremors, spasms, and poor muscle control. These medicines have been approved and on the market for almost 20 years. The combination of entacapone with carbidopa and levodopa has been shown to reduce end-of-dose “wearing-off” in patients with Parkinson’s disease to a greater degree than with entacapone alone or with the two-drug combination of carbidopa and levodopa.

The FDA is directing health-care professionals to follow standard prostate cancer screening recommendations for patients, and patients and caregivers to take medications as prescribed.

Data Summary

An unexpected finding in the Stalevo Reduction in Dyskinesia Evaluation–Parkinson's Disease (STRIDE-PD) trial was that a greater number of patients taking entacapone/carbidopa/levodopa were observed to have prostate cancer compared to those taking carbidopa/levodopa. STRIDE-PD evaluated the time to onset of dyskinesia in patients with Parkinson's disease taking entacapone/carbidopa/levodopa compared to those taking only carbidopa/levodopa. To further assess this safety concern, Novartis conducted an observational cohort study in patients with Parkinson’s disease comparing the incidence rate of prostate cancer in a cohort of patients treated with entacapone plus a conventional Parkinson’s disease treatment of dopa decarboxylase inhibitor/levodopa (DDCI/LD) with a cohort of patients treated with DDCI/LD plus either a dopamine agonist or a monoamine oxidase B inhibitor.

The study involved 11,396 men in Finland with Parkinson’s disease, 1,141 of whom received entacapone. A total of 359 prostate cancer cases occurred during an average follow-up time of 4.6 years, with 89 prostate cancer deaths during an average follow-up time of 4.7 years. Treatment with DDCI/LD with add-on entacapone (Group 1) was not associated with an increased risk of prostate cancer (hazard ratio [HR] = 1.05; 95% confidence interval [CI] = 0.76–1.44) or prostate cancer mortality (HR = 0.93; 95% CI = 0.43–1.98) compared to treatment with DCCI/LD without add-on entacapone (Group 2). Similarly, evaluation of the secondary objectives showed that longer cumulative treatment with entacapone was not associated with an increased risk of prostate cancer or prostate cancer death. The HR estimates for patients with more than 360 days cumulative treatment with entacapone were 0.82 (95% CI = 0.56–1.18) for prostate cancer incidence and 1.27 (95% CI = 0.59–2.72) for prostate cancer death, respectively, compared to patients with no entacapone treatment.

The study had limitations in the design and how the results were analyzed. The main limitations included the short period of time that entacapone/carbidopa/levodopa had been available in Finland compared to the long latency period of prostate cancer, the potential for decreased surveillance for prostate cancer in male patients with advanced Parkinson’s disease, and lack of information pertaining to important factors such as family history of prostate cancer and prior screenings for prostate cancer.

The FDA and Veterans Affairs (VA) Center for Medication Safety also conducted a retrospective cohort study of 17,666 U.S. male veterans with Parkinson’s disease treated with levodopa/carbidopa (n = 5,257), comparing add-on entacapone therapy to the control cohort, which received add-on therapy with a dopamine agonist or monoamine oxidase B inhibitor (n = 12,409). Patients were followed for occurrence of prostate cancer using data from the VA cancer registry. Mean follow-up time was 3.1 years and 4.0 years, respectively, in the entacapone and control cohorts. Twenty-three prostate cancer cases occurred in the entacapone cohort and 97 occurred in the control cohort. There was no difference in risk of prostate cancer between the cohorts for increased duration of cumulative entacapone treatment of more than 2 years (adjusted HR = 1.08; 95% CI = 0.46–2.51). Time since starting drug therapy and cumulative dose also did not suggest a difference in prostate cancer risk between the cohorts.

The low overall incidence rate of 1.8 cases of prostate cancer per 1,000 person-years compared to the age-adjusted rate of 1.3 per 1,000 U.S. males in the general population may reflect a possible bias in cancer ascertainment after Parkinson’s disease was diagnosed. This may be partly due to a decrease in screening for prostate cancer in the U.S., particularly in men with chronic medical conditions. This may have led to a potential decrease in prostate cancer detection, a limitation of the study.


The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.